# Telix Pharmaceuticals Limited American (TLX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $11.94, market value $4.1 billion.

## Valuation
- **P/E (trailing): 119.4×** (5-yr avg 157.8×, 3-yr avg 157.8×). Telix Pharmaceuticals Limited American trades at 119.4× trailing earnings, well below its own five-year average of 157.8×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 81.6×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 5.0×**. Each dollar of revenue is priced at 5.0×.
- **Price / book: 8.3×**. The shares trade at 8.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 84.2×**. Enterprise value is 84.2× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: -1.1%** (5-yr avg -0.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 0.8%**. The inverse of the P/E: 0.8% of the price is earned each year.

## Profitability
- **Gross margin: 53.1%**. Telix Pharmaceuticals Limited American keeps 53.1% of revenue after the direct cost of what it sells.
- **Operating margin: 3.7%**. 3.7% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: -0.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: -1.7%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 3.5%**. Return on all capital, debt included, is 3.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -0.6%**. Each dollar of assets produces -0.6% of profit.

## Growth
- **Revenue growth (1 yr): 55.6%**. Revenue grew 55.6% over the last year.
- **EPS growth (1 yr): -121.6%**. Earnings per share fell 121.6%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.98**. Debt is 0.98 times equity, moderate leverage.
- **Net debt / EBITDA: 5.1×**. It would take 5.1 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Altman Z-score: 4.53**. A Z-score of 4.53 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Telix Pharmaceuticals Limited American does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (3 analysts). 3 analysts cover Telix Pharmaceuticals Limited American; the consensus is strong_buy, with an average price target of $21.59 (+81% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 31.5%** (YTD 59.4%, 3-mo 28.4%). The shares are up 31.5% over twelve months including dividends.
- **From 52-week high: -4.3%** (90.1% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 57**. An RSI of 57 is neutral.
- **Beta (1 yr): 1.06** (volatility 54%). Beta of 1.06 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TLX · Page: https://foliofundamentals.com/stocks/tlx

Not investment advice.